RenovoRx raises 2026 revenue outlook to $3.75 million-$4.25 million
RNXT•RenovoRx forecast 2026 revenue of $3.75 million to $4.25 million. Third-quarter revenue was $1.07 million, while nine-month revenue rose 138% to $2.5 million.
1. Revenue and outlook
RenovoRx forecast 2026 revenue of $3.75 million to $4.25 million. Third-quarter revenue reached $1.07 million, more than quadrupling year over year, and nine-month revenue rose 138% to $2.5 million.
2. Commercial reach and cash
The company is targeting at least 36 active commercial cancer centers by year-end, compared with 26 as of November 5, 2026. It expects cash reserves to fund operations into the second half of 2027.
